Quanterix

Quanterix Current Liabilities

The Current Liabilities of Quanterix (QTRX) as of Nov 3, 2026 is 94.50 M USD. In the previous year, Current Liabilities was 58.39 M USD — a change of 61.85% (higher).

Current Liabilities

94.50 MUSD

YoY

61.85%

Last updated:

Current Liabilities of Quanterix is 2025 94.50 M USD. Current Liabilities of Quanterix was 2024 58.39 M USD. It decreases by 61.85% higher compared to the previous year.

The Quanterix Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
20.76 M USD
Jan 1, 2019
24.34 M USD
Jan 1, 2020
58.83 M USD
Jan 1, 2021
51.82 M USD
Jan 1, 2022
40.80 M USD
Jan 1, 2023
53.16 M USD
Jan 1, 2024
58.39 M USD
Jan 1, 2025
94.50 M USD
The Quanterix Current Liabilities history
YEARCurrent LiabilitiesYoY
94.50 MUSD+61.85%
58.39 MUSD+9.84%
53.16 MUSD+30.27%
40.80 MUSD-21.25%
51.82 MUSD-11.92%
58.83 MUSD+141.72%
24.34 MUSD+17.25%
20.76 MUSD-20.08%
25.97 MUSD+107.33%
12.53 MUSD+10.72%
11.31 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quanterix Stock analysis

What does Quanterix do? Quanterix Corp is a company specialized in the development and distribution of innovative instruments and technologies for the precise measurement of biomarkers. The company was founded in 2007 by a renowned expert team in biotechnology and diagnostics and is headquartered in Lexington, Massachusetts, USA. The history of Quanterix Corp began with the vision of finding new ways to diagnose diseases earlier and more accurately. The founders recognized that conventional diagnostic methods are often inaccurate and time-consuming, and saw great potential in improving diagnostics through the targeted measurement of specific biomarkers. They wanted to establish a company specialized in the development of technologies for this type of diagnostics. Today, Quanterix Corp is a leading provider of ultrasensitive tests and technologies for biomarker measurement. The company has various divisions, including Life Sciences and Diagnostics. In the field of Life Sciences, Quanterix offers instruments and kits for biomarker research and development. They utilize the patented Simoa technology (Single Molecule Array), which enables ultrasensitive biomarker measurement in conjunction with digital detection systems. In the field of Diagnostics, Quanterix offers ultrasensitive tests for various clinical applications. Here, the company works closely with industry partners and academic institutions to utilize the technology in clinical research and diagnostics. The goal is to optimize therapy decisions, monitor treatment outcomes, and identify early indications of diseases. Quanterix products are in demand worldwide and are used in various fields. For example, tests for neurodegenerative diseases such as Alzheimer's, Parkinson's, or ALS are offered. These tests can help track disease progression and improve diagnosis. Quanterix's ultrasensitive tests also play a role in oncology, where they can help detect cancer early or measure treatment success. Quanterix's business model is based on collaboration with partners from the pharmaceutical industry, academic institutions, and clinics. Quanterix sees itself as an enabler for the development of new therapies and diagnostic methods. Through collaboration with various partners, new innovations in research and diagnostics are made possible. In summary, Quanterix Corp is a leading company in the development and marketing of ultrasensitive tests and technologies for biomarker measurement. The company has various divisions and offers products for Life Sciences as well as Diagnostics. The Simoa technology allows for higher precision and accuracy in biomarker measurement. Quanterix's goal is to promote medical progress and provide patients with better diagnostic and therapeutic care through its technologies and tests. Quanterix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quanterix stock

Current Liabilities of Quanterix is 94.50 M USD in 2025.

Current Liabilities of Quanterix changed from 58.39 M USD to 94.50 M USD, representing a 61.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Quanterix since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Quanterix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Quanterix

All Key Metrics — Quanterix